Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 13/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.73 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.73 |
| ▸ | PGR | P06401 | 4/20 | 0.73 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | SHBG | P04278 | 2/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142384 | 1.00 | KMT2A (1.00) | KMT2AHIF1AHSD17B10CYP3A4NR3C1 | |
| SCHEMBL142385 | 1.00 | KMT2A (1.00) | KMT2AHIF1AHSD17B10CYP3A4NR3C1 | |
| SCHEMBL10393880 | 0.91 | KMT2A (0.84) | KMT2AHIF1AHSD17B10CYP3A4NR3C1 | |
| SCHEMBL137529 | 0.91 | KMT2A (0.84) | KMT2AHIF1AHSD17B10CYP3A4NR3C1 | |
| SCHEMBL9458663 | 0.91 | KMT2A (0.84) | KMT2AHIF1AHSD17B10CYP3A4NR3C1 | |
| SCHEMBL17714999 | 0.91 | KMT2A (0.84) | KMT2AHIF1AHSD17B10CYP3A4NR3C1 | |
| SCHEMBL13150977 | 0.91 | KMT2A (0.84) | KMT2AHIF1AHSD17B10CYP3A4NR3C1 | |
| SCHEMBL17726095 | 0.91 | KMT2A (0.84) | KMT2AHIF1AHSD17B10CYP3A4NR3C1 | |
| SCHEMBL137530 | 0.91 | KMT2A (0.84) | KMT2AHIF1AHSD17B10CYP3A4NR3C1 | |
| SCHEMBL6851992 | 0.91 | KMT2A (0.84) | KMT2AHIF1AHSD17B10CYP3A4NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230085402-A1 | BIOMARKERS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-03-16 | — | — | US | claimed |
| US-20210401798-A1 | LIPOXIN A4 ANALOGS AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-12-30 | — | — | US | claimed |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2020-02-04 | — | — | US | claimed |
| US-10088490-B2 | Assay for analytes using multiple receptors | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2018-10-02 | — | — | US | claimed |
| US-20180064666-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2018-03-08 | — | — | US | claimed |
| US-20170112792-A1 | ENHANCED ATRA-RELATED COMPOUNDS DERIVED FROM STRUCTURE-ACTIVITY RELATIONSHIPS AND MODELING FOR INHIBITING PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2017-04-27 | — | — | US | claimed |
| WO-2016145186-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2016-09-15 | — | — | WO | claimed |
| WO-2015143190-A1 | ENHANCED ATRA-RELATED COMPOUNDS DERIVED FROM STRUCTURE-ACTIVITY RELATIONSHIPS AND MODELING FOR INHIBITING PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2015-09-24 | — | — | WO | claimed |
| US-20150087677-A1 | METHODS FOR TREATING VESTIBULOTOXICTY | SENSORION (FR) | 2015-03-26 | — | — | US | claimed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | claimed |
| CN-1599613-A | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX INC (US) | 2005-03-23 | — | — | CN | claimed |
| EP-1448205-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2004-08-25 | — | — | EP | claimed |
| US-20040106216-A1 | Method of measuring drug-metabolizing enzyme activity, method of evaluating inhibition of drug-metabolizing enzyme activity, and composition for these methods | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2004-06-03 | — | — | US | claimed |
| US-20040072732-A1 | Use of ramoplanin to treat diseases associated with the use of antibiotics | NANOSHIFT, LLC | 2004-04-15 | — | — | US | claimed |
| US-20040022728-A1 | In vivo phenotyping for human cytochrome P450 3A activity | FURUTA TAKASHI (JP) | 2004-02-05 | — | — | US | claimed |
| EP-1378751-A2 | Method of measuring drug-metabolizing enzyme activity, method of evaluating inhibition of drug-metabolizing enzyme activity, and composition for these methods | Toyo Boseki Kabushiki Kaisha (JP) | 2004-01-07 | — | — | EP | claimed |
| WO-2003103699-A1 | USE OF RAMOPLANIN TO TREAT DISEASES ASSOCIATED WITH THE USE OF ANTIBIOTICS | VICURON PHARMACEUTICALS INC. (US) | 2003-12-18 | — | — | WO | claimed |
| WO-2003092617-A2 | COMBINATIONS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-11-13 | — | — | WO | claimed |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2003-06-26 | — | — | US | claimed |
| WO-2003030823-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-04-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401798-A1 | LIPOXIN A4 ANALOGS AND USES THEREOF | LTA4H, ALOX15B, LTB4R | KMT2A 3618/4885HIF1A 1354/4885HSD17B10 563/4885 |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | IL5, TSLP, TPMT | KMT2A 3786/4885HIF1A 1616/4885HSD17B10 1328/4885 |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | PIN1, RARB, RARA | KMT2A 1138/4885HIF1A 836/4885HSD17B10 2708/4885 |
| US-20180064666-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | PIN1, RARB, RARA | KMT2A 1138/4885HIF1A 836/4885HSD17B10 2708/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | KMT2A 3089/4885HIF1A 1602/4885HSD17B10 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.